- Home
- SAN vs SNY Comparison
SAN vs SNY Comparison
Compare SAN & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAN
- SNY
- Stock Information
- Founded
- SAN 1857
- SNY 1994
- Country
- SAN Spain
- SNY France
- Employees
- SAN N/A
- SNY N/A
- Industry
- SAN Commercial Banks
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- SAN Finance
- SNY Health Care
- Exchange
- SAN Nasdaq
- SNY Nasdaq
- Market Cap
- SAN 125.3B
- SNY 116.5B
- IPO Year
- SAN 1987
- SNY N/A
- Fundamental
- Price
- SAN $9.63
- SNY $49.77
- Analyst Decision
- SAN Strong Buy
- SNY Buy
- Analyst Count
- SAN 1
- SNY 2
- Target Price
- SAN N/A
- SNY $65.00
- AVG Volume (30 Days)
- SAN 4.7M
- SNY 2.7M
- Earning Date
- SAN 07-30-2025
- SNY 07-31-2025
- Dividend Yield
- SAN 1.75%
- SNY 3.21%
- EPS Growth
- SAN 17.29
- SNY 118.56
- EPS
- SAN 0.97
- SNY 8.65
- Revenue
- SAN $58,905,460,953.00
- SNY $53,714,621,258.00
- Revenue This Year
- SAN $22.90
- SNY $2.85
- Revenue Next Year
- SAN N/A
- SNY $6.65
- P/E Ratio
- SAN $9.60
- SNY $11.32
- Revenue Growth
- SAN 5.45
- SNY 15.65
- 52 Week Low
- SAN $4.43
- SNY $44.73
- 52 Week High
- SAN $9.70
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- SAN 71.89
- SNY 57.34
- Support Level
- SAN $8.29
- SNY $48.23
- Resistance Level
- SAN $8.97
- SNY $47.54
- Average True Range (ATR)
- SAN 0.11
- SNY 0.80
- MACD
- SAN 0.07
- SNY 0.23
- Stochastic Oscillator
- SAN 95.04
- SNY 94.92
About SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.